Literature DB >> 8492836

[Clinimetric evaluation of the Barthel Index, a measure of limitations in dailly activities].

R de Haan1, M Limburg, J Schuling, J Broeshart, L Jonkers, P van Zuylen.   

Abstract

OBJECTIVE: Evaluation of the clinimetric properties of the Barthel Index.
DESIGN: To measure disabilities in activities of daily living (ADL) and mobility by independent observers.
SETTING: Clinical and outpatient departments of Neurology of the University Medical Centre, Amsterdam. PATIENTS AND
METHOD: In 35 patients of the clinical and 25 patients of the outpatient department the stroke disabilities were assessed independently by three observers. The Barthel Index was evaluated in terms of score agreements, homogeneity, and construct validity.
RESULTS: There was an excellent concordance of total scores (mean kappa = 0.88; range 0.85-0.90) and single item scores (range mean values of kappa = 0.82-1.00). Repeated analyses, after exclusion of patients with maximum total scores, did not result in a significant reduction of these kappa values. The Barthel Index was a highly homogeneous scale (Cronbach's alpha = 0.96). All items contributed to this reliability in a balanced way. Factor analysis showed that the items on the scale described one common underlying trait. This factor explained 81% of the score variance.
CONCLUSION: The Barthel Index is a sound instrument to measure disabilities in ADL and mobility. The scale is suitable for use in both patient care and research.

Entities:  

Mesh:

Year:  1993        PMID: 8492836

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  21 in total

Review 1.  A review of health-related quality-of-life measures in stroke.

Authors:  B A Golomb; B G Vickrey; R D Hays
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Quality of life as an instrument for need assessment and outcome assessment of health care in chronic patients.

Authors:  G A van den Bos; A H Triemstra
Journal:  Qual Health Care       Date:  1999-12

3.  Long term effects of intensity of upper and lower limb training after stroke: a randomised trial.

Authors:  G Kwakkel; B J Kollen; R C Wagenaar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

4.  [The Barthel Index in geriatrics. A context analysis for the Hamburg Classification Manual].

Authors:  Norbert Lübke; Matthias Meinck; Wolfgang Von Renteln-Kruse
Journal:  Z Gerontol Geriatr       Date:  2004-08       Impact factor: 1.281

5.  The role of cognitive impairment in the quality of life after ischaemic stroke.

Authors:  V I Kwa; M Limburg; R J de Haan
Journal:  J Neurol       Date:  1996-08       Impact factor: 4.849

6.  Functional outcome and quality of life after angiography and operation for unruptured intracranial aneurysms. On behalf of the MARS Study Group.

Authors:  T W Raaymakers
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

7.  Assessment of post-stroke quality of life in cost-effectiveness studies: the usefulness of the Barthel Index and the EuroQoL-5D.

Authors:  N J A van Exel; W J M Scholte op Reimer; M A Koopmanschap
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

8.  The cost effectiveness of an early transition from hospital to nursing home for stroke patients: design of a comparative study.

Authors:  Ron W H Heijnen; Silvia M A A Evers; Trudy D E M van der Weijden; Martien Limburg; Jos M G A Schols
Journal:  BMC Public Health       Date:  2010-05-26       Impact factor: 3.295

9.  Measuring disability in stroke: relationship between the modified Rankin scale and the Barthel index.

Authors:  M Uyttenboogaart; G-J Luijckx; P C A J Vroomen; R E Stewart; J De Keyser
Journal:  J Neurol       Date:  2007-08-06       Impact factor: 4.849

10.  [Relationships between activities of daily living and glucose metabolism in geriatric patients with type 2 diabetes mellitus].

Authors:  Andreas Zeug; Joachim Lindner; Ulrich Julius
Journal:  Z Gerontol Geriatr       Date:  2009-06-20       Impact factor: 1.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.